Advanced Enzyme Technologies reported a 16% YoY revenue increase to INR 2,145 million and a 14% rise in PAT to INR 512 million for Q2 FY27. Strong growth in Bio-Processing and Animal Healthcare segments bolstered performance. The company also confirmed the successful completion of its share buyback program, acquiring 2.41 million shares at an average of INR 289.09 each.
Advanced Enzyme Technologies Q2 FY27 Results
Revenue grew 16% YoY to INR 2,145 million; PAT rose 14% YoY to INR 512 million.
Reader Takeaway: Strong growth in high-margin segments offset US market headwinds, supported by disciplined capital allocation through buybacks.
What just happened
Advanced Enzyme Technologies released its consolidated financial results for the quarter ended September 30, 2026. The company achieved a revenue of INR 2,145 million, representing a 16% growth compared to the same quarter last year. Net profit (PAT) for the period stood at INR 512 million, reflecting a 14% YoY increase. EBITDA margins improved to 34% from 33% in Q2 FY26. The firm also formally concluded its open-market share buyback, having acquired 2.41 million equity shares at an average price of INR 289.09.
Why this matters
The growth across key business segments confirms product demand. Bio-Processing revenue surged 43% YoY, while Animal Healthcare saw a 37% jump. These gains provided stability against a challenging US market, which has faced industry-wide tightness. The successful completion of the buyback indicates management's confidence in the company’s current cash position, which remains robust at approximately INR 610 crores.
What changes now
Management has reiterated its EBITDA margin guidance of 30% to 32% for the fiscal year. The company is accelerating R&D efforts, which grew to 4.3% of revenue this quarter compared to 3% in the previous year's corresponding quarter. Planned capital expenditure for the year remains set at INR 123 crores, with INR 52 million already utilized in the first half.
Risks to watch
Global inflationary pressures and energy price volatility remain primary operational risks. The recovery in the US market—a critical territory—is anticipated for later in the fiscal year, though management remains cautious due to client-side spending constraints. Geopolitical tensions continue to be a source of potential supply chain and cost instability.
Context metrics
- EBITDA for Q2 FY27: INR 721 million (up 20% YoY).
- R&D Spend: 4.3% of revenue.
- Cash Position: Approx. INR 610 crores post-buyback.
What to track next
Watch for the speed of the US market turnaround and the translation of increased R&D spend into new product launches over the next two quarters.